Exposure to ultraviolet (UV) radiation results in growth of clonal somatic mutation (CM) 62 harboring cell groups in clinically normal appearing skin and can cause non-melanoma skin 63 cancer (NMSC), the most common cancers in humans. CMs can be considered the earliest 64 detectable manifestations of photocarcinogenesis. Systematic evaluation of CMs is crucial to 65 understand early photo-carcinogenesis. Differences between CMs in sun-exposed (SE) and 66 non-SE (NE) areas are unknown. To address these problems, we developed a robust method to 67 quantitatively measure CMs in skin using targeted (5,500bp), ultra-deep (64,730X median 68 coverage), high-throughput sequencing in 450 matched SE and NE epidermal punch biopsies 69 obtained from clinically normal skin (n=13 individuals). In total we identified 638 mutations 70 including 298 UV-signature mutations (USMs). SE samples showed 3-fold higher rate of USM 71 and higher USM variant allele frequencies than NE. We identified areas in TP53, NOTCH1 and 72 GRM3 where mutation burden was significantly associated with UV-exposure. Six mutations 73 were almost exclusively present in SE epidermis and accounted for 42% of the overall 74 difference between SE and NE mutation burden. Cumulative Relative Clonal Area (CRCA) was 75 defined as the overall relative percentage of the sampled skin area affected by CM. UV-induced 76 DNA damage is a clinically relevant criterion and CRCA is a single metric of UV-damage. CRCA 77 was dramatically elevated (mean = 11.2 fold) in SE samples compared to NE. This study 78 represents the first analysis of clonogenic mutations in SE and NE human skin. The findings 79 unveiled previously unknown patterns of early mutations introduced by UV exposure. 80
2 and variant allele frequencies, were found between sun-exposed and -protected areas. 85 Furthermore, we identified specific genomic regions where mutation burden is significantly 86 associated with UV-exposure status. These findings revealed previously unknown mutational 87 patterns associated with UV-exposure, providing important insights into UV radiation's early 88 carcinogenic effects. The CRCA can be developed for quantitatively measuring subclinical skin 89 UV damage and field carcinogenesis. 90
Background 91 Ultraviolet (UV) light is responsible for over 5 million cases of skin cancer annually in the US, 92 which is more human malignancies than all other environmental carcinogens combined 1,2 . The 93 preferential location of UVB induced DNA lesions results in a specific pattern of so-called UV 94 signature mutations at dipyridine sites (C>T, CC>TT) 3 . In mammals, nucleotide excision repair 95 eliminates DNA lesions, but this mechanism of repair is error prone resulting in frequent 96 mutations. In most skin cancers the burden of UV signature driver mutations is high 3,4 . In 97 melanocytes, hypersensitive genomic regions related to UV exposure have been recently 98 identified 5 . While some cutaneous squamous cell carcinoma (cSCC) arise from visible 99 precancerous lesions, actinic keratoses (AKs), many cSCC arise in apparently "normal" skin 100 areas from precursors that are clinically invisible 6 . Therefore, visible precancers are an ominous 101 sign but not a good early measure of photocarcinogenesis. 102 TP53 mutations were detected by immunohistochemistry as p53 variants are dysfunctional 103 and accumulate due to impaired degradation 7,8 . These UV-induced TP53 mutations facilitate 104 clonal expansion of cells harboring them and therefore behave as early clonogenic mutations 105 (CMs) 9 . For two decades TP53 mutant keratinocyte cell clones were considered the earliest 106 manifestations of skin carcinogenesis 7, 8, 10 . Because p53 clonal immunopositivity could not be 107 efficiently quantified in human skin, detection of mutant TP53 for assessment of 108 photocarcinogenesis in clinical dermatology practice has been unattainable. The low abundance 109 of clonal DNA vs background DNA sequences previously limited efficient detection of early 110 mutated cell groups. However, with improved high throughput sequencing technology we have 111 finally reached the lower end of this threshold and efficient detection of CMs have become 112 possible. Using high throughput ultra-deep sequencing, CMs were found to be abundant in 113 clinically normal skin from sun-exposed sites in NOTCH1, NOTCH2, FAT1 and several other 114 genes besides TP53 11 . Prior attempts to establish a main-stream quantitative method for 115 assessing photodamage had limited success 12, 13 . A method that enables quantitative evaluation 116 of early photodamage is expected to help optimize personalized sun-protective measures and 117 may also serve as a tool for assessing the need and efficacy of early preventative treatment 118
interventions. 119
In the current work we present a bioinformatics analysis method for evaluating focused ultra-120 deep sequencing to quantify low variant allele frequency CMs in the epidermis and show 121 differences in CMs between sun-exposed and non-sun-exposed skin areas. We also present 122 evidence that limited genomic areas harbor most of the mutation burden difference between 123 sun-exposed and protected sites. 124 125 Methods 126
Samples: 127
A total of 464 normal human skin samples were collected from 13 Caucasian post-mortem 128 donors over the age of 55 years using Roswell Park's Rapid Tissue Acquisition Program under 129 a Roswell Park approved IRB protocol within 24 hours of death from frequently sun-exposed 130 (SE) sites (left dorsal forearm) and non-sun-exposed (NE) sites (left medial buttock). Exclusion 131 criteria included any visible skin abnormalities in the tissue areas. Eligible donors were identified 132 and clinically normal appearing skin was harvested. Skin samples were kept in tissue 133 preservation medium, Belzer UW cold storage solution (Bridge to Life, USA) at 4°C until 134 processed. All samples that could be processed within 36 hours or less after death were 135 included in the study. The mean age of the donors was 72.3 years (SD: ±8.2 years; range 60-136 80 years). The male to female gender ratio was 7:6, and 12/13 donors had no history of skin 137 cancer. 138
The adipose tissue was removed from each human skin sample using sterile scissors. The 139 samples were cut into strips wide enough to harvest 6 mm punches. The epidermis was 140 separated from the dermis by placing the strips in tubes containing 10 ml of 5U/ml Dispase II 141 (Stem Cell Technologies, USA) and incubated at 4°C overnight and at 37°C for 2-3 hours. After 142 Dispase digestion the specimens were placed in a petri dish containing a small amount of 1x 143 DPBS (Corning, USA) and using sterile tweezers, the epidermis was carefully removed from the 144 dermis. Using disposable biopsy punches, 1, 2, 3, 4 and 6 mm diameter epidermal pieces were 145 taken from the epidermal sheets and punched epidermal pieces were placed into a sterile 1.5 146 mL vials. In addition to the epidermal punches, large bulk pieces of dermis were also removed 147 from the skin samples using a disposable #15 blade and placed into a sterile 1.5 mL vial for use 148 as a germline control. 149
DNA isolation: 150
DNA samples were extracted using Purelink TM Genomic DNA mini kit (Invitrogen, USA). 151
Epidermal samples were digested using Proteinase K at 55°C heating block overnight following 152 the manufacturers recommendations. DNA was eluted with 28 μL of Molecular Biology Grade 153 Water (Corning, USA) for 1 and 2 mm punches or 36 μL of Molecular Biology Grade Water for 3, 154 4, and 6 mm punches. The isolated genomic DNA was stored at -20°C and the DNA 155 concentration of each extraction was measured using a Qubit fluorometer (Invitrogen, USA). 156
Ultra-deep Targeted Sequencing: 157
The sequencing libraries were generated using the TruSeq Custom Amplicon kit (Illumina, USA Here, the calculation of CRCA was based on the assumption that all mutations occur in one 195 chromosome of regular diploid genomic regions. Additionally, although we did not consider the 196 situation when multiple mutations occur in the same cell, we did identify mutations that occur on 197 the same reads and combined them into one mutation using MAC 16 . 198
Statistics: 199
The overall mutation numbers and VAFs between SE and NE groups were compared using the 200 Wilcoxon test. Group-specific markers, including mutations, genes, regions and signatures were 201 identified using the Fisher's exact test where the two variables in the contingency table were the 202 samples' sun-exposure status and mutational status. 203
Results 204

Ultra-deep sequencing of epidermal DNA samples using a customized focused panel 205
To generate a focused sequencing panel, targeting the most commonly mutated sequences in 206 normal human skin, we selected an area of focus based on a previous dataset 11 . All previous 207 mutations were assigned to 100 bp genomic segments, after sorting the segments by number of 208 mutations, we designed a panel to capture the top 55 segments from 12 genes (5.5 kb in total, 209 Table S1 ). The majority (65%) of the targeted segments came from the following 3 genes: 210 NOTCH1, NOTCH2, and TP53. Additionally, 79% of the targeted segments lie in protein coding 211 regions, and the remaining segments were mostly in introns. Furthermore, in the previous 212 dataset 87% of the samples harbored at least one mutation covered by this panel. 213
We used the focused panel to sequence a discovery cohort of 374 human skin samples from 214 13 post-mortem donors: 360 epidermal samples, equally acquired from both sun-exposed (SE) 215 and non-sun-exposed regions (NE) using 1 mm, 2 mm, 3 mm, 4 mm or 6 mm punch sizes. 216
From the same 13 donors, DNA from bulk NE dermis (n=14, 1 donor contributed 2 samples) 217 was isolated for germline controls. After initial analysis to determine the optimal punch size, we 218 tested a separate validation cohort of 90 epidermal samples from 9 of the 13 donors using the 219 most effective punch size (2 mm, as detailed in results "Optimization of punch size for USM 220 detection"). In total, the dataset contains 464 samples: 225 SE, 225 NE, and 14 dermal samples 221 as controls (Table 1 ) from 13 individuals. After sequencing, 85% of samples reached a 222 minimum of 10,000X coverage in at least 80% of the targeted region. The median of average 223 coverage across all samples was 64,730 (Table S2) 
Differentiating somatic mutations by SE and NE skin site type 227
To identify somatic mutations in both SE and NE specimens, we compared each epidermal 228 sample with its patient-matched dermal sample followed by an in silico error suppression to 229 remove germline polymorphisms and low-frequency technical artifacts. Moreover, we identified 230 dinucleotide and other complex mutation by re-analyzing the raw reads. Through these 231 processes a total of 638 mutations were identified, predominantly single nucleotide variants 232 (SNVs, n = 614 or 96.2%) or dinucleotide variants (DNVs, n = 20 or 3.1%). The median variant 233 allele frequency (VAF) of all mutations was 2.1% (range 0.1% -36.6%), and only 3% mutations 234 reached a VAF greater than 10%, a level that can generally be detected by conventional 235 sequencing (Table S3) . ("NOTCH1-10"), appeared to be non-differentiating between SE (n=48) and NE (n=40), even 242 though it harbored the highest number of mutations among all segments. An additional three 243 segments were also significantly enriched in SE samples (p<0.05), two in NOTCH1 ("NOTCH1-244 14" and "NOTCH1-19") and one in GRM3 ("GRM3-2"). On the gene level, mutations in SE 245 samples were significantly enriched in two genes (p<0.05): TP53 and GRM3, with SE/NE 246 mutation ratios of 6.3 and 4.3, respectively. Mutations identified in nine other genes did not 247 exhibit significant association with sun-exposure status either on the gene or segment level: 248 NOTCH2, ARID1A, SALL1, SCN1A, ERBB4, FAT4, FGFR3, ADGRB3 and PPP1R3A. 249
In order to identify potential hotspot mutations and regions associated with UV-exposure, all 250 mutations were ordered by their genomic locations. Upon ordering, one specific region in NE 251 samples, TP53 (p.217-280), appeared to be "mutation exempt" in comparison to surrounding 252 regions. In contrast however, this region became highly mutated in SE samples (Figure 2a ). In 253 another recent study including RNA sequences of both SE and NE normal skin samples, four 254 mutations were found in this region, all from SE samples (Table SX) 19 . On the mutation level, six 255 mutations were significantly enriched in SE samples: TP53 R248W, NOTCH1 P460L, NOTCH1 256 S385F, NOTCH1 E424K, TP53 G245D and NOTCH1 P460S, and nearly all of them were 257 exclusively found in SE samples (p<0.05, Figure 2b) . Five of the six enriched mutations were 258 found in both discovery and validation cohorts, suggesting they were unlikely to be caused by 259 batch-effect. Unexpectedly, one specific mutation (NOTCH1 E424K) was associated with 260 significantly elevated VAFs (median = 10%, p<0.001, Wilcoxon test), about five-fold higher than 261 other mutations (median = 2.1%). Of the 19 mutations with VAFs above 0.1, five were NOTCH1 262 E424K. Through protein structure modelling (Figure 2c ), we found that the NOTCH1 E424K 263 mutation is predicted to disrupt the binding of NOTCH1 to delta-like canonical ligand 4 (DLL4), a 264 negative regulator of the Notch signaling pathway 19 . By prohibiting formation of a salt bridge 265 between NOTCH1 E424 and DLL4 K189/R191, the mutation E424K creates a repulsive force 266 that inhibits DLL4 binding 20 . Based on the biological role of DLL4 and NOTCH1, we expect the 267 mutation to promote epithelial proliferation 21, 22 . The overall prevalence of the NOTCH1 E424K 268 mutation in our dataset is 2.7%. For comparison, in GINIE cBioPortal 23 , NOTCH1 E424K is 269 mutated in 1.3% of cutaneous SCCs, 0.04% in melanomas, and is rarer in other cutaneous or 270 non-cutaneous malignancies (Table S5) . To help capture the mutational burden of a patient in a single metric, an overall measurement 304 of UV-induced DNA damage was developed by distilling the VAFs and number of USMs: 305
Cumulative Relative Clonal Area (CRCA), defined as the overall percentage of biopsied skin 306 area covered by USMs in a patient skin punch (Figure 4b) . Here, we disregard whether 307 mutations occurred independently or were present in the same clone. Hence, CRCA does not 308 provide an exact measure of the mutated cell population, but rather serves as a relative 309 measure of the mutation burden in the sampled area. To minimize the potential for repeat 310 counting of co-occurring mutations in the same cells, co-occurring mutations were identified, 311 primarily dinucleotide CC>TT mutations, and counted as one mutation. When counted 312 separately by sun-exposure status, the median CRCA, i.e. the relative mutational load of 313 biopsied skin areas, across the 13 patients was 6.1% (range 1.4-14.2%) in SE and 1.4% (range 314 0.1-4.0%) in NE samples. In matched samples from the same individuals comparing SE versus 315 NE skin, the average CRCA was 11.2-fold higher (range = 1.4 -55.0-fold). The CRCAs were 316 calculated using only USMs. If all CMs were included, the all-CM-CRCA would be only 2.2-fold 317 higher (range = 0.8 -5.6-fold) in SE skin (data not shown). 318
319
The effect of punch size on USM detection 320
In the discovery cohort, we sought to compare different punch sizes to determine the most 321 efficient one for detecting USMs. Theoretically, although larger punches likely contain more 322 clones, they tend to become less effective for detecting smaller clones due to a dilutional effect 323 by other clones harboring no mutations or different mutations (Figure 5a) . Overall, USMs were 324 detected in 54% of the SE, which was significantly greater than the detection rate of 21% of the 325 NE (p < 0.001, Fisher's exact test). Among all 5 punch sizes, 2 mm punches were most likely to 326 capture CMs, positive rate of 64%, and had the most significant difference between SE and NE 327 samples (p < 0.0001, Figure 5b) . Thus, only 2mm punches were collected in the 90-sample 328 validation cohort. In the validation cohort, similarly, a higher number of USMs were identified in 329 the SE skin and the positive rate of USMs (69%) was consistent with the discovery cohort. 330
When combining the discovery and validation cohorts, the SE samples had the highest 331 positive rate of 67% for USMs in 2 mm samples and were significantly higher than NE samples 332 (p < 0.001), followed by 60% in 4 mm (p < 0.05), and 54% in 3 mm (p < 0.05). Interestingly, the 333 largest punch size of 6 mm and the smallest, 1 mm, showed lower positive USM rates in SE 334 samples of 53% (6mm) and 36% (1mm), respectively. The 2 mm punches were selected for 335 analysis because the detection rate of SE skin USMs in 2 mm punches was significantly higher 336 than 1 mm (p <0.01) and results in less scaring than larger punches. In all NE samples, positive 337 USM rates ranged from 17-30% (Figure 5c) . Moreover, the punch size also affected the 338 detected VAFs of the mutations. Specifically, in SE samples, larger punches were associated 339 with smaller VAFs. The VAFs' standard deviation was the highest in 1 mm punches (8.9%) and 340 decreased with punch size: 2 mm (4.3%), 3 mm (2.8%), 4 mm (2.6%) and 6 mm (1.7%). This 341 trend, between VAF range and punch size, did not occur in NE samples (Figure 5d) . 342
Considering the high positive USM rate and VAF, the 2 mm punch size was the most effective in 343 detecting USMs. This study represents a comprehensive analysis of individual-matched human skin samples 372 to detect UV radiation's mutational effects. We optimized our approach for detecting UV-induced 373 CMs by: 1) acquiring matched SE/NE skin samples of each individual to control for aging and 374 other environmental factors; 2) separating epidermal from dermal layers decreases non-375 epidermal background DNA quantity; 3) ultra-deep DNA sequencing for maximized sensitivity, 376 followed by error-suppression using matched dermal samples to exclude sequencing and 377 alignment errors. Consistent with previous studies 11,19 , CMs were widespread in epidermal 378 samples. As expected mutation burden and VAFs were significantly elevated in SE samples. 379
The mutational signatures of the current CMs are consistent with those previously found in skin 380 cancers, confirming the validity of the detected CMs. Markedly, our unique approach allowed us 381 to identify several important new insights about epidermal CMs: 1) the existence of "mutation-382 exempt" regions in human genomes. Although mutations frequently occur across most of the 383 sequenced regions in NE skin, presumably due to metabolism and aging related intrinsic or non-384 UV extrinsic factors, the mutation-exempt regions harbor no mutations prior to UV exposure. 385
Interestingly, the mutation-exempt property of these regions is not maintained upon exposure to 386 UV radiation. Further studies are warranted to determine whether the mutation-exempt regions 387 are caused by active protection or by a passive selective advantage, and to explore how this 388 mechanism is bypassed after exposure to UV radiation. 2) in SE skin, USMs were found to be 389 significantly enriched in Glutamate Metabotropic Receptor 3 (GRM3), which was previously 390 identified as a potential therapeutic target in melanoma 28 , but not reported as a cancer driver in 391 cutaneous SCC; 3) we identified six mutations that were almost exclusively mutated in SE skin. 392
All six mutations had been previously reported in human cancers. Three of these mutations in 393 TP53 R248W and G245D were highly recurrent with hundreds of occurrences reported in the 394
Catalogue Of Somatic Mutations
In Cancer 29 and all six of these mutations are amongst the 395 most common mutations found in human cutaneous squamous cell carcinomas in the 396 cBioPortal suggesting that the presence of these mutations may be representative of an early 397 phase of carcinogenesis. 398
Future clinical utility directed our approach, and these results demonstrate the feasibility of 399 using a small panel of genomic regions (5.5 kb) to quantitatively measure UV-induced CMs. We 400 established Relative Cumulative Clonal Area (CRCA) as a combined measure of mutation 401 burden and clone sizes, that showed an overall 11.2-fold difference between patient-matched 402 SE/NE samples. The most effective punch size in capturing CMs in the current study was 2 mm 403 and is clinically favorable as it leaves relatively smaller scars due to the small diameter punch. 404
However, a non-invasive skin sampling method may provide even wider accessibility to 405 epidermal sampling. In addition, the efficiency of this panel is related to the performance of 406 sequencing method and mutation calling algorithm, which will likely be improved with adoption 407 of more sensitive future methods focusing on the genomic hotspots that are most sensitive to 408 UV exposure. 409
The current study focused on the most frequently mutated regions in sun-exposed skin 410 samples defined by the mutations in a previous study 11 . However, we note that many of these 411 regions are mutated in both sun-exposed and non-sun-exposed skin samples, suggesting many 412 mutations in these regions were unrelated to UV exposure. In fact, only 6 of 55 original regions 413 were found to harbor significantly enriched mutations in SE samples. with its size calculated to match the clonal area harboring the mutation. 3 mm was not shown as 501 it was obtained by cutting a 6 mm punch into quarters. b. In the discovery cohort, 2 mm was 502 found to be the most efficient size in differentiating CRCA from SE and NE skin samples by p 503 value. c. Distribution of numbers of USMs per sample at each punch size, combining both the 504 discovery and validation cohorts. d. VAF of USM detected in different size punches. The size of 505 the dot indicates the approximate relative area of cells containing the mutation. VAFs of USMs 506 detected from larger punches are associated with smaller variations, which was only observed 507 in SE samples. 508 
